Cingulate Inc.

Stage 4 · Declining · week 11→4 today

As of Oct 22, 2026, Cingulate is in Stage 4, the downtrend phase, now in its first week (since Oct 22, 2026). It closed at $4.66, 60.0% below its 52-week high and below its 200-day average, which is rising.

$4.66

+0.00% today

$67.8M · Micro cap

Market Neutral — Fading

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is CING early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 55w

S2 13w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 55w → S1 7w → S4 11w → S1 7w → S4 13w → S1 6w → S2 5w → S3 4w → S4 13w → S1 3w → S2 13w → S3 8w → S4 8w → S1 10w → S4 1w current

Total tracked: 165 weeks across 15 stage runs.

CING among Biotechnology136th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…136	CINGCingulate Inc.	Stage 4 · wk 1	71	−6.4%

vs 52W High

-60.0%

$3.33 lo$11.66 hi

60.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 1

1w13w26w

Week 1, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-14.2%

200 DMA: $5.43 · rising

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

0.68x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-6.4%

+0.4%

-17.1%

YTD

+6.4%

+21.0%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S41→4

Wk 1 · Vol 0.68x

2026-10-21S1

Wk 10 · Vol 1.12x

2026-10-20S1

Wk 10 · Vol 0.95x

2026-10-19S1

Wk 10 · Vol 0.40x

2026-10-16S1

Wk 10 · Vol 1.98x

2026-10-15S1

Wk 10 · Vol 1.54x

2026-10-14S1

Wk 9 · Vol 0.90x

2026-10-13S1

Wk 9 · Vol 0.62x

2026-10-12S1

Wk 9 · Vol 0.25x

2026-10-09S1

Wk 9 · Vol 0.23x

2026-10-08S1

Wk 9 · Vol 0.62x

2026-10-07S1

Wk 8 · Vol 0.93x

Moving averages & range

50 DMA

$5.03

200 DMA

$5.43

52W High

$11.66

52W Low

$3.33

5D Low

$4.36

Resistance levels (recent highs)

20d High

$4.95

60d High

$5.87

120d High

$5.89

250d High

$11.66

Next resistance

+6.2%

to 20d High

ROE

-198.7%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.8

Cingulate: quick answers

What stage is Cingulate in?

As of Oct 22, 2026, Cingulate (CING) is in Stage 4, the downtrend phase. It entered Stage 4 on Oct 22, 2026 and is in its first week there. What the four stages mean

Is Cingulate in an uptrend?

No. Cingulate is in a Stage 4 downtrend. It trades 14.2% below its 200-day average, which is rising.

How far is Cingulate from its 52-week high?

Cingulate closed at $4.66 on Oct 22, 2026, 60.0% below its 52-week high of $11.66. Its 52-week low is $3.33.

How has Cingulate performed over the past year?

As of Oct 22, 2026, Cingulate is up 21.0% over the past year and up 6.4% so far in 2026.

Which sector and industry is Cingulate in?

Cingulate is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.